Close Menu

NEW YORK – SkylineDx said Tuesday it has entered an agreement with BioInvent International to characterize gene expression and immunological signatures in the tumors of patients before and after they have been treated with BI-1206, BioInvent's lead therapy candidate for patients with non-Hodgkin lymphoma and solid cancers.

The companies will research and develop predictive immunological signatures to help identify patients who are likely to show clinical responses if treated with BI-1206, Rotterdam, Netherlands-based Skyline Dx said.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.